A rare case of acute leukemic presentation of blastic plasmacytoid dendritic cell neoplasm without cutaneous lesions

• Published in: Annals of laboratory medicine 2014, 34(2), , pp.148-151
• Main Authors: Yu, Shinae, Kwon, Min-Jung, Kim, Kyungeun, Koo, Dong-Hoe, Woo, Hee-Yeon, Park, Hyosoon
• Format: Article
• Language: English
• Subjects: Acute Disease; Adult; Bone Marrow Cells - cytology; CD4 Antigens - metabolism; CD56 Antigen - metabolism; Flow Cytometry; Hematologic Neoplasms - diagnosis; Hematologic Neoplasms - pathology; Humans; Interleukin-3 Receptor alpha Subunit - metabolism; Letter to the Editor; Leukocyte Common Antigens - metabolism; Lymph Nodes - metabolism; Lymph Nodes - pathology; Male; Tomography, X-Ray Computed; 병리학
• ISSN: 2234-3806; 2234-3814
• DOI: 10.3343/alm.2014.34.2.148

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a clinically aggressive phenotype arising from CD4/CD56-expressing plasmacytoid dendritic cell precursors [1]. BPDCN was categorized under “AML and re- lated precursor neoplasms” by the 2008 WHO classification, with most cases having been previously classified as blastic nat- ural killer (NK)-cell lymphoma/leukemia or agranular CD4+, CD56+ hematodermic neoplasm [2]. BPDCN cells generally ex- press CD4, CD56, CD123, and TCL-1 but are negative for other T-, B-, NK-cell, or myeloid markers [3]. Clinically, patients with this disease typically present with a high incidence of cutaneous involvement described as generalized, localized, or solitary mac- ules, plaques, and/or tumors, as the first manifestation, followed by involvement of bone marrow (BM), peripheral blood (PB), and lymph nodes (LNs). BM involvement usually occurs with leukemic progression of advanced or relapsed disease and is associated with a poor prognosis [4]. Diagnosis of leukemic BP- DCN without cutaneous manifestation is rare. Here, we report a 41-yr-old man who was diagnosed with BPDCN in the absence of skin manifestation. KCI Citation Count: 3